

# Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

## Frontiers in Digestive Research and Practice

<b>Name</b>	Chang Hwan Choi
<b>Affiliation</b>	Chung-Ang University of College of Medicine
<b>Country</b>	South Korea
<b>Major Field</b>	Gastroenterology

### Educational Background

Mar. 1991 - Feb. 1997	Yonsei University of College Medicine
Mar. 1999 - Feb. 2001	Yonsei University, School of Postgraduate M.S.
Mar. 2001 - Feb. 2004	Ph.D. in gastroenterology, internal medicine, Yonsei University

### Professional Experience

Mar. 1997 - Feb. 1998	Internship; Yonsei University Severance Hospital
Mar. 1998 - Feb. 2002	Residency in Internal medicine; Yonsei University Severance Hospital
Mar. 2002 - Feb. 2004	Clinical Fellow in gastroenterology; Yonsei University Severance Hospital
July. 2013 - June 2014	Visiting Scholar in Gastroenterology, University of North Carolina, School of Medicine at Chapel Hill
Mar. 2006 – present	Professor in Gastroenterology, Internal Medicine (Subspeciality: lower gastrointestinal diseases), Chung-Ang University College of Medicine

### Main Scientific Publications

1. Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use. *Dig Liver Dis.* 2025 Jan;57(1):176-183.
2. Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets. *Gut Pathog.* 2024 Aug 26;16(1):44.
3. Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity. *Korean J Intern Med.* 2024 Jan;39(1):68-76.
4. Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform-Infrared Spectroscopy Coupled with Machine Learning Algorithms. *Metabolites.* 2023 Dec 19;14(1):2.
5. Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis. *Therap Adv Gastroenterol.* 2023 May 2;16:17562848231168199.
6. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. *Therap Adv Gastroenterol.* 2023 Mar 18;16:17562848231154103.
7. Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease. *Intest Res.* 2023 Jan;21(1):148-160.
8. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. *Intest Res.* 2023 Jan;21(1):61-87.